About
MediBioSense is at the global forefront of medical wearable technologies. We are revolutionising the future of healthcare. By providing wearable (medically approved) technology and integrated healthcare solutions we are changing the way health is measured and tracked and transforming the landscape of medical treatment.
Our wearable devices allow for real-time monitoring of the following clinical physiological data: Heart Rate, ECG, Respiration Rate, Temperature, Blood Oxygen (Sp02), Posture, and Activity Levels.
VitalPatch is a health-monitoring device in the growing field of Tele-Health. Never before has such a small, elegant device provided so much valuable information for physicians and nurses. This state-of-the-art biosensor monitors eight physiological measurements continuously, in real-time. The VitalPatch has FDA/CE (Class IIa) certification for medical use with clinical papers referencing its effectiveness worldwide.
Accompanying the VitalPatch is MBS HealthStream which revolutionises the way health and wellness is measured and tracked at a clinical grade level.
MBS HealthStream is a secure cloud-based dashboard designed for clinical settings where providers can increase access to healthcare, improve the quality of patient care and reduce costs utilising the easy to use interface to set customised alerts on patient by patient level with the results being available on any internet connected device with a web browser meaning your patients can be monitored by clinicians as they move.
The use of the VitalPatch can apply not only in Virtual Ward and at home monitoring settings, the integrated Cardiac/ECG reporting service can detect 21 arrhythmia’s in real-time, replacing the traditional Holter with an unobtrusive wearable patch (CE/FDA medically approved) therefore, reducing waits ECG results, costly outpatient appointments, and non-compliant patients. The VitalPatch wearable sensor provides 24/7 full medical analytics and reporting immediately to the clinicians within an AI driven opinion to speed up the analysis process.
Key Facts
MediBioSense flagship product the VitalPatch is currently being utilised in 49 countries around the world with over 200,000 vital patches being sold in the last 3 years within the US alone.
MediBioSense utilising its VitalPatch technology contributed to major benefits for patients and clinicians alike with its implementation in a recent Virtual Ward implementation for patients with Respiratory and Frailty conditions in the NHS.
Published evidence has shown:-
- A 2,451.99% Return on Investment for a 20 patient virtual ward in 6 months based on health system costs for inpatient stays
- Patients on the virtual ward reported a 92.5% satisfaction score based on the NHS Friends and Family Test
- Patients on the Respiratory virtual ward experienced a 82% reduction in re-admisisons compared with normal admissions for the same conditions
- Staff utilising the technology reported a 100% satisfaction score and confidence in the technology
Successes in UK/NHS
The VitalPatch has been utilised across the NHS within Virtual Ward settings, for clinical studies in conjunction with Universities and within a primary care driven community cardiology setting where it has been used as an alternative to the ECG holter where it was proven to reduce waiting lists for patients suffering from palpitations. We are continuing to work with the NHS to spread the rollout of the VitalPatch and for others to experience the significant return on investment experienced by our customers to date whilst continuing to drive excellent patient and staff experience and confident scores. We are continuing to improve our portfolio of products with a view to supporting patients who would benefit from spot monitoring based virtual ward and other remote monitoring schemes. Successful schemes to date has resulted in over 2,450 patients benefiting from remote monitoring of BP levels over a 7 dayCompany details
Solutions
Augmenting healthcare professionals
Delivering advanced patient care
Providing advanced screening and diagnostics
Specialism
Decision Support and treatment planning
Digitally-enabled out of hospital care
Specialised diagnostics
Company details
Want to connect with this innovator?
Make an enquiryWebsite
www.medibiosense.comRevenue
£0-2m
Funding Status
Not seeking funding
Markets already exporting to
UK, USA, Mexico, South Africa, European Union, UAE
Desired Markets
Global
Desired customer types
Business to Business, Business to Customer, Public Sector, Private Sector